Next Article in Journal
Crosstalk between Stress Granules, Exosomes, Tumour Antigens, and Immune Cells: Significance for Cancer Immunity
Next Article in Special Issue
The Design and Development of a Multi-HBV Antigen Encoded in Chimpanzee Adenoviral and Modified Vaccinia Ankara Viral Vectors; A Novel Therapeutic Vaccine Strategy against HBV
Previous Article in Journal
Immunogenicity and Efficacy of a Recombinant Human Adenovirus Type 5 Vaccine against Zika Virus
Previous Article in Special Issue
Immunization with the H5N1 Recombinant Vaccine Candidate Induces High Protection in Chickens against Vietnamese Highly Pathogenic Avian Influenza Virus Strains
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Vaccines
Volume 8
Issue 2
10.3390/vaccines8020171
vaccines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

A Prime-Boost Immunization Strategy with Vaccinia Virus Expressing Novel gp120 Envelope Glycoprotein from a CRF02_AG Isolate Elicits Cross-Clade Tier 2 HIV-1 Neutralizing Antibodies

by
Rita Calado
1,
Joana Duarte
1,
Pedro Borrego
1,
José Maria Marcelino
1,2,
Inês Bártolo
1,
Francisco Martin
1,
Inês Figueiredo
1,
Silvia Almeida
3,4,
Luís Graça
3,
Jorge Vítor
5,
Frederico Aires da Silva
6,
Inês Dias
6,
Belmira Carrapiço
6 and
Nuno Taveira
1,2,*
1
Instituto de Investigação do Medicamento (iMed.ULisboa), Faculdade de Farmácia, Universidade de Lisboa, 1649-003 Lisboa, Portugal
2
Centro de Investigação Interdisciplinar Egas Moniz (CiiEM), Instituto Universitário Egas Moniz, 2829-511 Monte de Caparica, Portugal
3
Faculdade de Medicina, Instituto de Medicina Molecular, Universidade de Lisboa, 1649-02 Lisboa, Portugal
4
Post-Graduate Program in Infectious Diseases, and Department of Social Medicine, Center of Health Sciences, Federal University of Espirito Santo, Vitória 29075-910, Brazil
5
Biochemistry and Human Biology Dept, Faculdade de Farmácia, Universidade de Lisboa, 1649-003 Lisboa, Portugal
6
Faculdade de Medicina Veterinária, Universidade de Lisboa, 1300-477 Lisboa, Portugal
*
Author to whom correspondence should be addressed.
Vaccines 2020, 8(2), 171; https://doi.org/10.3390/vaccines8020171
Submission received: 2 March 2020 / Revised: 2 April 2020 / Accepted: 4 April 2020 / Published: 7 April 2020
(This article belongs to the Special Issue Genomic Medicine and Advances in Vaccine Technology and Development in the Developing and Developed World)
Browse Figures
Versions Notes

Abstract

Development of new immunogens eliciting broadly neutralizing antibodies (bNAbs) is a main priority for the HIV-1 vaccine field. Envelope glycoproteins from non-B-non-C HIV-1clades have not been fully explored as components of a vaccine. We produced Vaccinia viruses expressing a truncated version of gp120 (gp120t) from HIV-1 clades CRF02_AG, H, J, B, and C and examined their immunogenicity in mice and rabbits. Mice primed with the recombinant Vaccinia viruses and boosted with the homologous gp120t or C2V3C3 polypeptides developed antibodies that bind potently to homologous and heterologous envelope glycoproteins. Notably, a subset of mice immunized with the CRF02_AG-based envelope immunogens developed a cross-reactive neutralizing response against tier 2 HIV-1 Env-pseudoviruses and primary isolates. Rabbits vaccinated with the CRF02_AG-based envelope immunogens also generated potent binding antibodies, and one animal elicited antibodies that neutralized almost all (13 of 16, 81.3%) tier 2 HIV-1 isolates tested. Overall, the results suggest that the novel CRF02_AG-based envelope immunogens and prime-boost immunization strategy elicit the type of immune responses required for a preventive HIV-1 vaccine.
Keywords: HIV-1 vaccine; Recombinant Vaccinia virus; envelope glycoproteins; non-B-non-C clades; BALB/c mice; New Zealand White rabbits; broadly neutralizing antibodies HIV-1 vaccine; Recombinant Vaccinia virus; envelope glycoproteins; non-B-non-C clades; BALB/c mice; New Zealand White rabbits; broadly neutralizing antibodies
Graphical Abstract

Share and Cite

MDPI and ACS Style

Calado, R.; Duarte, J.; Borrego, P.; Marcelino, J.M.; Bártolo, I.; Martin, F.; Figueiredo, I.; Almeida, S.; Graça, L.; Vítor, J.; et al. A Prime-Boost Immunization Strategy with Vaccinia Virus Expressing Novel gp120 Envelope Glycoprotein from a CRF02_AG Isolate Elicits Cross-Clade Tier 2 HIV-1 Neutralizing Antibodies. Vaccines 2020, 8, 171. https://doi.org/10.3390/vaccines8020171

AMA Style

Calado R, Duarte J, Borrego P, Marcelino JM, Bártolo I, Martin F, Figueiredo I, Almeida S, Graça L, Vítor J, et al. A Prime-Boost Immunization Strategy with Vaccinia Virus Expressing Novel gp120 Envelope Glycoprotein from a CRF02_AG Isolate Elicits Cross-Clade Tier 2 HIV-1 Neutralizing Antibodies. Vaccines. 2020; 8(2):171. https://doi.org/10.3390/vaccines8020171

Chicago/Turabian Style

Calado, Rita, Joana Duarte, Pedro Borrego, José Maria Marcelino, Inês Bártolo, Francisco Martin, Inês Figueiredo, Silvia Almeida, Luís Graça, Jorge Vítor, and et al. 2020. "A Prime-Boost Immunization Strategy with Vaccinia Virus Expressing Novel gp120 Envelope Glycoprotein from a CRF02_AG Isolate Elicits Cross-Clade Tier 2 HIV-1 Neutralizing Antibodies" Vaccines 8, no. 2: 171. https://doi.org/10.3390/vaccines8020171

APA Style

Calado, R., Duarte, J., Borrego, P., Marcelino, J. M., Bártolo, I., Martin, F., Figueiredo, I., Almeida, S., Graça, L., Vítor, J., Aires da Silva, F., Dias, I., Carrapiço, B., & Taveira, N. (2020). A Prime-Boost Immunization Strategy with Vaccinia Virus Expressing Novel gp120 Envelope Glycoprotein from a CRF02_AG Isolate Elicits Cross-Clade Tier 2 HIV-1 Neutralizing Antibodies. Vaccines, 8(2), 171. https://doi.org/10.3390/vaccines8020171

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop